• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

ImmunoCellular Therapeutics Names New CEO


December 16, 2016

ImmunoCellular Therapeutics (Los Angeles, CA) announced that its Board of Directors has appointed Anthony Gringeri, Ph.D, as Chief Executive Officer.   The appointment follows the decision by Andrew Gengos to resign the position of CEO. Mr. Gengos will continue to play an active role with the company as a member of the Board of Directors, the company reports.   Dr. Gringeri has served as ImmunoCellular's Senior Vice President of Strategic Resources since August 2013. He joined ImmunoCellular from ViaCyte, where he was Vice President and Chief Development Officer. He previously served as Chief Operating Officer for Amsterdam Molecular Therapeutics.

Related Videos